mRNA-0217/S001 / Shanghai Xinpu BioTech - LARVOL DELTA

Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Ruijin Hospital | N=60 ➔ 34 | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Nov 2024 ➔ Jun 2026

Enrollment change • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • KRAS • TP53